Why has the Mesoblast share price tumbled 10% so far in August?

The stock in the regenerative medicine company has faltered this month amid a capital raise.

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • It's been a rough month so far for the Mesoblast share price, tumbling 10% since the end of July to close at 85 cents today
  • Much of that fall came when the company announced a successful $65 million placement two weeks ago
  • The Mesoblast share price is currently down 40% year to date

The Mesoblast Limited (ASX: MSB) share price has come crashing down recently, tumbling 9.57% since the end of last month.

Much of that fall came amid a capital raise that saw shares in the biotechnology company offered for 75 cents each. The slump also follows a 54% surge in the Mesoblast share price during July.

The Mesoblast share price closed at 85 cents on Wednesday, down from 94 cents at the end of last month.

For context, the All Ordinaries Index (ASX: XAO) has lifted 0.9% so far this month.

So, what's been weighing on the Mesoblast share price lately? Let's take a look.

What's been dragging on the Mesoblast share price lately?

Interestingly, the Mesoblast share price has plunged this month despite not trading for much of the first fortnight.

The stock entered a trading halt before the market opened on 4 August and didn't return to trade until the following week.

At the time, the company told the market its shares were halted as it underwent a private placement. Though, all details of such a placement remained a secret until it returned to trade.

It wasn't until 9 August that Mesoblast announced it had completed the capital raise. The placement saw its coffers injected with an additional $65 million after it sold 86.7 million new shares for 75 cents apiece.

The funds were partially earmarked to go towards launching the company's lead drug candidate, remestemcel-L. Some of the cash will also be used to fund the phase three trial of its rexlemestrocel-L.

The Mesoblast share price plummeted 6.4% the day it was removed from the freezer.

It's also worth noting Mesoblast released its most recent quarterly activities and cash flow report in the final session of last month. Its stock slipped 2% that day. Thus, some of its August slump may have been representative of a belated reaction to the release.  

At least the stock is well versed in trading in the red. It has tumbled 40% since the start of 2022. It's also currently 57% lower than it was this time last year.

For comparison, the All Ordinaries has dropped 9% year to date and 7% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »